Client News

http://dustinlee.ca/?_escaped_fragment_=/ja-jp/%E6%A4%9C%E7%B4%A2/q=torquel can you buy Lyrica over the counter Pasadena, CA — SAFCell, Inc. has signed option agreements with both Caltech and Northwestern to exclusively license all patents related to hydrogen generation using solid acid electrolyte membranes and related technologies. With these rights, their proprietary proton cells can be used to generate ultra-pure hydrogen from a host of “liquid hydrogen carriers,” such as ammonia, methanol and methylcyclohexane. With an aim to decarbonize global energy demands with cutting edge science, the SAFCell team is excited about exclusive access to these proven technologies.

SAFCell, working with researchers at both Caltech and Northwestern University, have demonstrated hydrogen generation from liquid and gaseous fuels, including the three leading “liquid hydrogen carriers.” Decarbonizing global energy demands with clean hydrogen depends on moving vast quantities of the energetic fuel, a task made safer and greatly simplified by liquid hydrogen carriers. Hydrogen is expected to become cost competitive with natural gas, but the traditional methods of transporting hydrogen as a highly compressed gas (i.e., typically at 2,000-10,000 psi) or as a liquid (at -253℃) are prohibitively expensive. Most energy producers plan to go green by attaching hydrogen to a liquid molecule. The hydrogen is then transported and stored in this “liquid hydrogen carrier” form until it arrives
at point of use, where it is converted back into hydrogen or used directly. Liquid hydrogen carriers are also especially effective for hard to electrify sectors, such as heavy-duty transportation, off-grid housing, industrial heating, and chemical production.

The use of hydrogen in many energy intensive sectors, particularly for transportation applications like heavy duty trucking and aviation, has the potential to completely eliminate greenhouse gas and particulate emissions. However, the current “hydrogen fuel cell” technology developed for transportation applications requires ultra-pure hydrogen, and cannot run on the liquid hydrogen carriers being considered for bulk hydrogen transport and storage. Hence, a device is needed to extract hydrogen from its liquid form. SAFCell has now secured world-wide rights to use solid acid electrolyte technologies to convert liquid hydrogen carriers into ultra-pure, compressed hydrogen.

Commenting on the intellectual property, SAFCell’s CEO, Calum Chisholm said:
SAFCell now has the rights and ability to convert simple liquid fuels directly into ultrapure, compressed hydrogen in one economic and highly efficient step. This is a unique property our intermediate temperature solid acid systems, as other technologies are either too cold to perform the hydrogen liberation step, or too hot to scale to the very large-scale systems needed for this application.

Dr. Chisholm anticipates a rapidly growing demand for this hydrogen generation technology as the world’s production of green hydrogen is expected to increase nearly 500 times by 2030. “The current methods for transporting and storing hydrogen will not scale to the use of hydrogen as a world-wide energy carrier. In the very near future, large scale hydrogen will be converted into a simple liquid and SAFCell will be ready to convert it back to hydrogen or electricity at point of use,” said Dr. Chisholm.

buy Lyrica mexico About SAFCell Inc.
SAFCell is an electrochemical energy company with a focus on unique solid acid electrolytes
that are used to convert real world liquid and gaseous fuels into electricity or ultra-pure
compressed hydrogen. SAFCell is partnering with world-leading fuel cell and hydrogen
system integrators to produce solid acid systems with power ranges from tens of watts to
megawatts and hydrogen production rates from kilograms to thousands of kilograms per day.
Web: https://safcell.com
Tweet: @SAFCell_Inc

We support companies by improving sustainability metrics at a cost that is competitive with landfill tipping fees.

Visit Arqlite at https://www.arqlite.com for more information.

For more information, please visit Stocastic at https://www.stocastic.com/

Visit the Pictor Labs website at https://pictor-labs.com.

WHOLE BLOOD POINT OF CARE METABOLIC MEASUREMENT – PROJECT SUMMARY

THIS SBIR PHASE II PROJECT WILL TRANSLATE PHASE I TECHNICAL INNOVATIONS IN SENSOR MATERIALS AND A PROTOTYPE DEVICE INTO A FULLY FUNCTIONAL POINT OF CARE TECHNOLOGY FOR WHOLE BLOOD BIOMARKER MONITORING. IT WILL CULMINATE IN A COMPLETE DRAFT OF A 510(K) CLEARANCE APPLICATION TO THE U.S. FOOD & DRUG ADMINISTRATION (FDA).

CURRENTLY, NO COMMERCIAL FDA CLEARED POINT OF CARE DEVICE IS AVAILABLE FOR DIRECT MEASUREMENT OF THIS BIOMARKER IN WHOLE BLOOD. ALL LARGE CLINICAL INSTRUMENTS REQUIRE SEPARATION OF PLASMA FROM WHOLE BLOOD VIA CENTRIFUGATION PRIOR TO MEASUREMENT. FURTHER, CURRENT CLINICALLY USED MEASUREMENTS, WHICH RELY ON PLASMA SEPARATED FROM WHOLE BLOOD, SUFFER FROM INACCURATE RESULTS FROM PRE-ANALYTICAL VARIABILITY IN SAMPLE HANDLING.

PHASE I COMPLETED TECHNICAL INNOVATIONS SUPPORTED BY THE NATIONAL SCIENCE FOUNDATION YIELDED 1) INCREASED SENSOR SPECIFICITY, BY ELIMINATING SIGNALS FROM INTERFERENTS, 2) INCREASED SENSOR SENSITIVITY THROUGH SENSING MATERIAL IMPROVEMENTS, AND 3) DIRECT POINT OF CARE MEASUREMENT FROM WHOLE BLOOD, INSTEAD OF PLASMA SEPARATED EX-SITU FROM THE MEASUREMENT DEVICE WHICH ELIMINATED PRE-ANALYTICAL VARIABILITY IN SAMPLE HANDLING.

THIS NOVEL POINT OF CARE WHOLE BLOOD MEASUREMENT DEVICE WILL BE USED TO IMPROVE AT-HOME MANAGEMENT OF THE ~10,000 PEOPLE LIVING WITH THESE RARE METABOLIC DISORDERS AND AS A NEWBORN SCREENING TO IMPROVE IDENTIFICATION OF THE ~1/3500 NEWBORNS WITH RARE METABOLIC DISORDERS OUT OF THE 3.9 MILLION ANNUAL BIRTHS IN THE UNITED STATES. ULTIMATELY, MANUFACTURING OF CONSUMABLE, SINGLE USE SENSORS AND SENSOR READERS WILL CREATE NEW JOBS IN THE UNITED STATES.

IN THIS DIRECT PHASE II PROJECT, SEQUITUR HEALTH CORP. WILL PARTNER WITH ARIZONA STATE UNIVERSITY AND MAYO CLINIC TO INNOVATE A PROCESS FOR MASS PRODUCTION OF THE LABORATORY-SCALE SENSORS DEVELOPED FROM THE PHASE I PROJECT AND SUBSEQUENTLY ANALYTICALLY AND CLINICALLY VALIDATE THE MASS-PRODUCED SENSORS AND READER TECHNOLOGY FOR FDA 510(K) CLEARANCE.

Sequitur Health

1 2 3 4